Background
Methods
Eligibility criteria
Information sources
Search strategy
Study selection
Data collection process and assessment of methodological quality
Summary measures
Results
Study selection
Author | Country | Publication year | Sample size | Age Mean ± SD | Age Range | Drugs | Ref |
---|---|---|---|---|---|---|---|
Abdurashhed Abdul | Nigeria | 2005 | 25 | 49.3 ± 16.8 | 20-73 | Amo,Cip,Cla,clind,Eryth,Met,tet | [20] |
Aboderin Oladiipo | Nigeria | 2007 | 32 | 48.6 ± 16.23 | 20-73 | Amo,Tet,Cip, Cla,Eryth,Met,,Rifamp | [21] |
Adeniyi A.Bolande | Nigeria | 2012 | 52 | – | 10-90 | Aug,Amo,Tet,Eryth,Clox,Genta,Cotr,Chlor,Nitro,Nalid,Oflox,Cla,met,Cefs,Ceph,Vanc,Tob,Kana,Clind | [63] |
Angol C Denish | Uganda | 2017 | 142 | 40 ± 18 | 13-85 | Cla,quino | [64] |
Ani Agatha.E | Nigeria | 1999 | 87 | – | – | Amo,Cla,Met,Tet | [26] |
Asrat Daniel | Ethiopia | 2004 | 50 | – | – | Cla,Eryth,Tet,Met,Amo | [24] |
Bouihat Najat | Morocco | 2016 | 255 | Met, Cla, levo, Rifam, Amox, Tet | [33] | ||
Fathi Marwa S | Egypt | 2013 | 60 | 46.7 ± 8.8 | 50–60 | Cla,Cip,Tet,Met,Amo | [22] |
Ghaith Doaa | Egypt | 2016 | 100 | 44 ± 11 | 21-60 | Cla | [65] |
Hadibi D.Fazia | Algeria | 2016 | 195 | Cla | [66] | ||
Harries A.D | Malawi | 1992 | 136 | – | 18-70 | Met,Pen,Tet,Amo | [29] |
Harrison Ute | Nigeria | 2017 | 577 | Met,Amox,Cla,Tet | [67] | ||
Kimanga Andrew Nyerere | Kenya | 2010 | 70 | – | – | Amo,Met,Cla | [4] |
Lwai-lume L | Kenya | 2005 | 267 | 45.4 ± 17.6 | 15 - 85 | Cla,Amo,Tet,Met | [68] |
Mansour Khansa Ben | Tunisia | 2010 | 273 | 38.3 | – | Amo,Met,Cla | [27] |
Nicoline F. Tanih | South Africa | 2010 | 200 | – | – | Amo,Cip,Cla,Gent,Eryth,Met,Tet | [31] |
Nicoline F. Tanih | South Africa | 2011 | 254 | 45.5 + 15.7 | 5-93 | Met,Cla | [55] |
Nicoline F. Tanih | South Africa | 2013 | 254 | – | – | Cla, Quin | [34] |
Ngoyi, Ontsira Nina E | Congo Brazavil | 2015 | 63 | 43.9 ± 15.3 | 17- 76 | Cla,Tet,Quin, | [32] |
Ndip N.Roland | Cameroon | 2008 | 77 | 44.5 ± 15.7 | 15–77 | Met,Tet,AMo,Cla | [69] |
Seck Abdoulaye | Senegal | 2009 | 40 | – | – | Met, Cip,Amo | [28] |
Seck Abdoulaye | Senegal | 2013 | 108 | 45.3 | 18–93 | Amo, Tet,Met, Cla, Lev | [30] |
SeckaOusman | Gambia | 2013 | 169 | 30 | 1 ½ -70 | Met,Cla,Tet,Amo | [25] |
Thor-H. Henriksen | Ethiopia | 1999 | 290 | – | – | Amo,Dox,Met | [18] |
Sherif May | Egypt | 2004 | 48 | – | 2-17 | Amp,Cla,Eryth,Azyth,Met,Cip | [23] |
Smith I. Stella | Nigeria | 2001 | 532 | – | – | Cip,Met,Amox,Pip,Ery,Imep,Gent,kan,ofl,Nor,Cef | [70] |
Total | 4324 | 1 ½-93 |
Description of the studies
AUTHOR | METHOD USED | SUSCEPTIBILITY METHOD | INTERPRETATION CRITERIA | REF | ||
---|---|---|---|---|---|---|
Isolate | CULTURE | PCR | ||||
Abdurashhed et al | 20 | YES | NO | disc diffusion | NCCLS | [71] |
Aboderin et al. 2007 | 31 | YES | NO | disc diffusion | NCCLS | [71] |
Adeniyi et al. 2012 | 33 | YES | NO | disc diffusion | not documented | – |
Angol C Denish | 21 | NO | YES | – | – | [64] |
Ani et al. 1999 | 55 | YES | NO | E-test | Thomsbbery, C. (1985);Hachem, C. Y., (1996). | |
Asrat et al. 2004 | 50 | YES | NO | E-test | Cederbrant G,1993 | [74] |
Bouihat Najat | 255 | YES | YES | E-test Disc diffusion | CLSI | [33] |
Fathi et al... 2013 | 16 | YES | YES | E-test, Disc diffusion | CLSI | [75] |
Ghaith et al. 2016 | 70 | NO | YES | – | – | [65] |
Hadibi et al. 2016 | 91 | NO | YES | – | – | [66] |
Harries et al. 1992 | 50 | YES | NO | disc diffusion | not documented | – |
Harrison et al. 2016 | 111 | YES | YES | E-Test | CLSI | [67] |
Kimanga et al. 2000 | 65 | YES | NO | E-test | CLSI | [75] |
Lwai-Lume et al. 2005 | 108 | YES | NO | E-test | NCCLS | – |
Mansour et al. 2010 | 273 | YES | YES | E-test | Chaabouni H, (2004) | [76] |
Nicoline et al. 2010 | 191 | YES | NO | disc diffusion | CLSI | [75] |
Nicoline et al. 2011 | 200 | YES | YES | disc diffusion | CLSI | [75] |
Nicoline et al. 2013 | 78 | YES | YES | disc diffusion | N. F. Tanih (2010) | [31] |
Ngoyi et al. 2015 | 56 | NO | YES | NA | NA | – |
Roland et al. 2008 | 132 | YES | YES | disc diffusion | NCCLS | [71] |
Seck et al. 2009 | 40 | YES | NO | E-test | Megraud F (1999) | [77] |
Seck et al. 2013 | 108 | YES | YES | E-test | CLSI | [75] |
Secka et al. 2013 | 64 | YES | YES | E-test | not documented | – |
Sherif et al. 2004 | 48 | YES | NO | E-test | not documented | – |
Smith et al. 2001 | 245 | YES | YES | E-test, Disc diffusion | NCCLS | [70] |
Thor-Henric et al. 1999 | 19 | YES | NO | disc diffusion | Cederbrant G,.1993 | [74] |
TOTAL | 2430 |
Susceptibility testing
H.pylori mutations in Africa
DRUGS | Isolates tested for mutations | Total mutation detected | Type of Mutations | Frequency (%) |
---|---|---|---|---|
CLARITHROMYCIN | 334 | 97 | A2143G | 49(50.5%) |
A2142G | 24 (25%) | |||
A2147G | 17(17.5%) | |||
A2146C | 1 (1%) | |||
A2142C | 2(2%) | |||
A2144G | 2(2%) | |||
A2143C | 2(2%) | |||
QUINOLONES | 60 | 40 | D87I | 16 (40%) |
D91N | 14 (35%) | |||
D91G | 1(2.5%) | |||
D91Y | 1(2.5%) | |||
N87 K | 8 (20%) | |||
METRONIDAZOLE | 66 | 56 | RdxA (41) | 41(73.2%) |
FrxA (15) | 15(26.8%) | |||
TETRACYCLINE | 40 | 1 | AGA926-928 | 1 (100%) |